Defunct Company
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
58
NCT02430363
Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
Phase: Phase 1/2
Role: Collaborator
Start: Mar 31, 2013
Completion: Jun 30, 2018